For several high-profile growth stocks, share price performance in 2025 ended up being forgettable. These stocks didn't just underperform. They lost ground. However, if you can take a step back and look at the bigger picture, there are at least a couple of these cases where this weakness is likely only a temporary setback. Indeed, these pullbacks offer an opportunity for investors to get in front of a recovery in 2026. Where to invest $1,000 right now? Our analyst team just revealed what they believe are ...

Neve Yarak, Israel, Jan. 15, 2026 (GLOBE NEWSWIRE) -- N2OFF, Inc. (NASDAQ: NITO) (“N2OFF” and the “Company”), a drug discovery company that is also investing in solar energy assets based on the RTB (Ready to Build) business model, today highlighted a newly published peer-reviewed study co-authored by Prof. Ciro Leonardo Pierri, co-founder of MitoCareX Bio Ltd. (“MitoCareX Bio”), N2OFF’s wholly-owned subsidiary. The article, appearing in the Journal of Translational Medicine, investigates SLC25A mitochondria ...

Neve Yarak, Israel, Jan. 05, 2026 (GLOBE NEWSWIRE) -- N2OFF, Inc. (NASDAQ: NITO) (“N2OFF” and the “Company”), a drug discovery company that is also investing in solar energy assets based on the RTB (Ready to Build) business model, announced advancement in its European portfolio via its partnership with Solterra Renewable Energy Ltd. (“Solterra”). As announced on December 29, 2025, key milestones in Germany project, which includes solar energy PV and storage assets, have reduced permitting risks, unlocked va ...

Core Insights - N2OFF, Inc. is advancing its European portfolio through a partnership with Solterra Renewable Energy Ltd, focusing on solar energy assets and reducing permitting risks [1][5] Germany Update - The flagship project in Germany is on track for Q3 2026 approval, with no objections received during the public consultation phase, indicating strong regulatory support [9] - An amendment to the development agreement has been executed, providing Solterra with approximately €280,000 in advance funding, resulting in project-level savings exceeding $1.69 million [9] Italy Update - Formal planning applications for Sicilian battery storage projects have been submitted, with approvals targeted for H2 2026, contingent on the absence of material objections [4][9] - N2OFF will evaluate optimal value realization paths, including project sale or construction and operation, based on strategic partner decisions [4] Financial Highlights - The strategic renegotiation in Germany has optimized returns, demonstrating a disciplined and capital-efficient approach to project management [9] - The Italian battery storage projects are positioned for high-upside monetization flexibility, with options for sale or build-and-operate strategies [9]

AI-powered drug discovery and biodefense company engages pharma on CNS programs amid rising deal activity SACRAMENTO, Calif., Dec. 18, 2025 /PRNewswire/ -- Lunai Bioworks Inc. (NASDAQ: LNAI), an AI-driven pharmaceutical discovery company, was featured in International Business Times in a year-end analysis highlighting the company's strategic positioning, active partnership discussions, and favorable market dynamics as 2025 draws to a close. International Business Times also examined several company-specific ...

Why are you doubling down and what is the money being used for. Well, first of all, thanks so much for for having us here. It's a really exciting time for the company we're coming out of this year with a series of research breakthroughs where we've now shown that we can use A.I. to design molecules that we never even thought was going to be possible. So we're really using this money to double down on that research agenda.The models show no signs of of slowing down, and then also really growing the team and ...

Company Overview & Culture - Isomorphic Labs aims to solve all disease through an interdisciplinary culture [1] - The company is actively recruiting diverse talent, including machine learning experts and drug discovery scientists [1] Recruitment Focus - Isomorphic Labs is seeking a wide variety of people [1] - Current roles are available, with a link provided in the comments section [1]

Company Overview - Isomorphic Labs welcomed HRH Prince Daniel of Sweden, Marcus Wallenberg, and future business leaders to its London head office [1] - Max Jaderberg and Rebecca Paul shared how Isomorphic Labs is leading a new era of drug discovery with AI [1] AI in Drug Discovery - Isomorphic Labs believes frontier AI can unlock deeper scientific insights [1] - The company aims for faster breakthroughs and life-changing medicines through AI [1]

Core Concept - The term "meme stock" refers to publicly traded companies that experience rapid increases in market value due to trading activity on online platforms, often driven by community interest [1] Company Overview - Recursion Pharmaceuticals (NASDAQ: RXRX) is a biotech company focused on drug discovery utilizing artificial intelligence [2] - The company has been suggested to be a meme stock by Jim Cramer, a notable figure in the investment community [5] Stock Performance Analysis - Recursion Pharmaceuticals has been on a downward trend for most of the year, with volatility typical for clinical-stage biotechs [4] - There is limited interest in Recursion on social media, which does not support the classification as a meme stock [4] - Following Cramer's suggestion on October 22, the stock has not consistently increased, underperforming compared to broader equities [6] Investment Viability - A characteristic of meme stocks is that their fundamentals do not correlate with stock performance; however, Recursion's financial performance does not align with the meme stock narrative [7] - Despite being labeled as a meme stock, Recursion Pharmaceuticals may not be a viable investment option [8]

Core Insights - N2OFF, Inc. has completed the acquisition of MitoCareX Bio Ltd., focusing on the precision oncology market and leveraging MitoCareX's proprietary MITOLINE algorithm for drug discovery [1][2][3] Company Overview - MitoCareX Bio Ltd. is a biotechnology company utilizing MITOLINE, an algorithm for 3D modeling of mitochondrial transport proteins, to develop therapies for difficult-to-treat cancers [2][4] - The company targets mitochondrial SLC25 transport proteins, which are crucial in the metabolic reprogramming of aggressive cancers like lung and pancreatic cancer, with a projected global therapeutic market exceeding $50 billion by 2026 [3][4] Strategic Direction - MitoCareX aims to optimize hit-to-lead medicinal chemistry and pharmacokinetic profiling in 2026, with the goal of nominating a preclinical development candidate [5] - The company is exploring strategic collaborations and licensing agreements to expand MITOLINE's applications, creating non-dilutive revenue opportunities [6][7] Long-Term Vision - The long-term strategy includes preparing for IND-enabling studies to transition MitoCareX toward clinical readiness while establishing MITOLINE as a scalable discovery engine [7][8] - MitoCareX's approach combines mitochondrial biology, computational modeling, and precision oncology, positioning it uniquely in the biotech sector [8][9] Innovation and Value Creation - The MITOLINE algorithm enables high-throughput in silico screening of small molecules, accelerating the drug discovery process [4][10] - The company aims to build a repeatable, data-driven discovery platform that transforms mitochondrial biology into sustained innovation and value creation [10][11]